[Single-dose versus 5-day cotrimoxazole therapy in acute symptomatic urinary tract infections in the female. A prospective randomized study].
In a prospective trial, 67 women (outpatients and inpatients) with acute symptomatic infection of the lower urinary tract were randomly selected to receive either a single dose of oral co-trimoxazole or conventional five-day therapy with the same drug. Diagnostic and bacteriological problems were investigated. Both regimens showed similar effectiveness with 91% (five-day therapy) and 100% (single-dose therapy) clinical and bacteriological cure. There were no co-trimoxazole-resistant species in vitro and no therapy side effects. As in other studies, we found that in more than one-third of the cases enterococcus was the responsible bacteria for the infection. This is an important finding because of its resistance to cephalosporins.
D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D001431:Bacteriological Techniques; D001437:Bacteriuria / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011446:Prospective Studies; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole
Einmaldosis versus 5-Tage-Cotrimoxazol-Therapie akuter symptomatischer Harnweginfekte bei Frauen. Eine prospektive randomisierte Studie.